-
Selling 4.5 yuan of expired drugs The pharmacy was fined 100,000 yuan
Time of Update: 2021-03-09
In accordance with the relevant provisions of Article 117, paragraph 1, of the Drug Administration Law of the People's Republic of China, the Market Supervision Bureau of Yandu District confiscates expired Chinese medicine tablets and illegal income of the parties concerned, and punishes them with a fine of ten times the value of the goods (based on 10,000 yuan) and a fine of 100,000 yuan.
-
Margenza significantly reduces the risk of disease progress/death and re-introduces medicine to China
Time of Update: 2021-03-09
It's worth noting that Margenza is the first HER2 targeted therapy to significantly improve progressive survival (PFS) in a head-to-head Phase 3 clinical trial compared to Roche's ace biologic agent Herceptin (Herceptin, generic name: trastuzumab, tratojutatin monoantigen), which is approved to market as a new treatment option for her2-positive metastasis breast cancer patients.
-
New use of poison - A's cream, B's honey
Time of Update: 2021-03-09
It wasn't until 1998, when the New England Journal of Medicine reported on studies at memorial Sloan-Kettering Cancer Center and Cornell Medical School that As2O3 was treated for APL patients and was almost completely relieved, that the international medical community widely accepted the therapeutic effects of As2O3 on APL.
-
Sudden! The general manager of a multinational pharmaceutical company in China has left his appointment
Time of Update: 2021-03-09
Sammy Karam, Abbott's senior vice president and head of emerging markets for the pharmaceutical business, announced the news to employees that Mr Kim would leave Abbott to seek other career opportunities, with the last working day on March 5.
-
The latest news from the national collection came out of the fifth batch of time
Time of Update: 2021-03-09
With the normalization of national harvesting, varieties, time have become traceable, pharmaceutical enterprises should do a good job in advance of market research, adjust their product structure, m
-
Report that a pharmaceutical company has been fined 150,000! Another drug company was fined 420,000 for failing to make the difference in loading
Time of Update: 2021-03-09
Photo One of the pharmaceutical companies was fined because of the report, and the other pharmaceutical company was fined for failing to qualify for the difference in the amount of kidney capsules.
-
Nexpovio, the first nuclear output inhibitor, is about to be approved for review by China
Time of Update: 2021-03-09
Selinexor is the world's first oral selective nuclear output inhibitor (SINE), approved in the United States under the name Xpovio, for the treatment of the hematoma field's two major adaptors - multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL).
-
Good policy has been introduced the whole country will add a number of three-level hospitals
Time of Update: 2021-03-09
, "county and village medical service capacity improvement" received 2,756 million yuan in financial subsidies, county-level hospitals as the leading hospitals become the focus of construction and upgrading objects.
to establish and improve the rural three-level medical and health service network based on county-level hospitals, township hospitals and village health rooms.
-
State Office issued with volume procurement "20", special procurement included in the national procurement!
Time of Update: 2021-03-09
On January 29th, the General Office of the State Council issued the Opinions on Promoting the Normal institutionalization of drug centralized belt procurement, which made an important deployment for t
-
Gan Li Pharmaceuticals Phase 1 candidate drug was approved by the FDA Fast Track
Time of Update: 2021-03-09
The one-year survival rate of glioblastoma was 39.3%.
the second and fifth years after diagnosis, the survival rate dropped to 16.9 per cent and 5.5 per cent, respectively.
survival time for untreated patients is only three months.
-
When the fourth batch of 90 standard medicines is reported
Time of Update: 2021-03-09
On December 17th, Hubei Provincial Health Insurance Bureau issued a Notice on the Reporting of Procurement Data on the Scope of The Fourth Batch of National Organizations' Centralized Drug Purchase Varieties, notifying medical institutions at all levels to fill in the procurement demand online, requiring the completion of data reporting as required by 17:00 on December 21, and completing the examination and reporting of medical institutions in their jurisdictions by 17:00 on December 25.
-
Vaccines - a never-out-of-time "golden good"
Time of Update: 2021-03-09
our bodies recognize that the protein should not exist and produce T lymphocytes and B lymphocytes, which remember how to fight the virus that causes COVID-19 if we are infected in the future.
-
According to the survey, the growth rate of medical expenses in the country's basic medical insurance coverage rate of 96.8% has slowed
Time of Update: 2021-03-09
Basic health insurance coverage reached 96.8 percent, and the growth rate of medical expenses slowed in terms of health insurance coverage and utilization rate, the report data showed that the coverage rate of basic medical insurance in the survey areas reached 96.8 percent, an increase of 1.7 percentage points over 2013, and the participation rate of basic medical insurance for residents in urban and rural areas was 96.1 percent and 97.6 percent, respectively.
-
Myovant/Pfizer releases clinical data for Relugolix Phase 3, a new drug for endometriosis
Time of Update: 2021-03-09
A combination of relugolix, estradiol and acetaminophen once a day can reduce clinically significant symptoms in endometriosis women within a year, according to the results of the latest Phase III long-term expansion study published by Pfizer and Myovant.
-
The release of the latest documents from the national collection distribution enterprises is equally great
Time of Update: 2021-03-09
the whole country, Shanghai issued a supplementary document On January 20, Shanghai Sunshine Pharmaceutical Purchasing Network released the "National Drug Centralized Purchase Shanghai Regional Supplemental Document (GY-YD2021-1)", which provides detailed requirements for enterprise declaration, drug distribution, quality testing, tri-party agreement, payment of goods, and use of selected drugs in Shanghai.
-
After showing good news, pharmaceutical companies will meet their tenth consecutive limit
Time of Update: 2021-03-09
Like Hengrui Pharmaceuticals such an announcement of the market value of the magic, that is the research and development pipeline up, a new drug clinical registration step by step for the camp, are relying on products to fight the world.
-
First! Well-known medical enterprises Bekang Medical is about to go public
Time of Update: 2021-03-09
Public information shows that Beckon Medical's PGT-A kit can screen embryos for normal development before implantation (a chromosomal disease often associated with failed IVF implants), the first and first high-volume gene sequencing kit approved by the State Drug Administration, marking the birth of China's PGT third-generation IVF "certificated" industrial genetic testing market.
-
A brief analysis of the change of the location of pharmaceutical enterprises in the context of industrial digitalization to make site selection more efficient!
Time of Update: 2021-03-09
Enterprise location decision-makers to obtain site selection clues, the need for continuous field visits, by the cost of time and cross-regional space constraints, coupled with the biopharmaceutical industry's unique complex approval procedures, resulting in the vast majority of pharmaceutical companies in the traditional site selection decision-making will be more biased towards standardized supporting parks.
-
A pharmaceutical company is punished for not treating drugs that are over-time
Time of Update: 2021-03-09
Party: Guangxi Huatianbao Pharmaceutical Co., Ltd. Illegal Facts: Law enforcement officials of our Bureau from October 27, 2020 to October 28, 2020, in accordance with the law to carry out daily supe
-
Haier Bio intends to sell its stake in the U.S. company
Time of Update: 2021-03-09
According to the announcement, Haier Bio recently received notice from Mesa, a U.S. subsidiary, that Thermo Fisher intends to acquire a full stake in Mesa and has signed a merger agreement that applies to U.S. Delaware law.
